Alector Inc. Stock News

Alector (NASDAQ:ALEC) initiated with Buy rating and $44 (52% upside) price target at Stifel.Aridis Pharmaceuticals (NASDAQ:ARDS) initiated with Buy rating and $18 (193% upside) price target at Roth Ca

Passage Bio has filed to raise $126 million in an IPO of its common stock. The firm is a pre-clinical biopharma working on monogenic treatments for central nerv

Alector Inc (NASDAQ:ALEC) VP Calvin Yu sold 63,541 shares of the business’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $30.04, for a total value of

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (N

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 5.) Alector Inc (NASDAQ: ALEC ) (announced gr

Alector Inc (NASDAQ:ALEC) insider Robert Paul sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $28.00, fo

Alector Inc (NASDAQ:ALEC) shares traded up 7.1% during mid-day trading on Tuesday after an insider bought additional shares in the company. The company traded as high as $31.00 and last traded at $30.

While most investors may focus exclusively on the millennials, it’s the baby boomers that could be the most relevant for Wall Street.

The FDA designates Alector's (ALEC +6.8%) AL101 for Fast Track review for the treatment of patients with progranulin gene mutations causing frontotemporal dementia (FTD).Phase 1-stage AL101 is

Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AL101 f

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (N

Investors who take an interest in Alector, Inc. (NASDAQ:ALEC) should definitely note that the Independent Director...

Investors who take an interest in Alector, Inc. (NASDAQ:ALEC) should definitely note that the Independent Director...

Passage Bio has filed to raise $125 million in an IPO, although the final figure may differ. The firm is advancing a pipeline of genetic treatment candidates fo

Alector Inc (NASDAQ:ALEC) Director David M. Wehner bought 20,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were bought at an average cost of $28.19 per s